Document:

<PAGE>

                                                                     Exhibit 4.1

                                 CERTIFICATE OF
                  VICE CHAIRMAN AND CHIEF FINANCIAL OFFICER AND
                            VICE PRESIDENT, TREASURER
                             AND ASSISTANT SECRETARY
                      PURSUANT TO SECTIONS 201, 301 AND 303
                                OF THE INDENTURE

                                                          Dated:  April 23, 2004

                  The undersigned, ALAN H. LUND and PAMELA S. HENDRY, do hereby
certify that they are the duly appointed and acting Vice Chairman and Chief
Financial Officer and Vice President, Treasurer and Assistant Secretary,
respectively, of INTERNATIONAL LEASE FINANCE CORPORATION, a California
corporation (the "Company"). Each of the undersigned also hereby certifies,
pursuant to Sections 201, 301 and 303 of the Indenture, dated as of November 1,
2000 (the "Indenture"), between the Company and The Bank of New York, as
Trustee, as amended, that:

                  A.       There has been established pursuant to resolutions
duly adopted by the Board of Directors of the Company (a copy of such
resolutions being attached hereto as Exhibit B) and by a Special Committee of
the Board of Directors (a copy of such resolutions being attached hereto as
Exhibit C) a series of Securities (as that term is defined in the Indenture) to
be issued under the Indenture, with the following terms:

                  1.       The title of the Securities of the series is
                  "Medium-Term Notes, Series P" (the "Medium-Term Notes").

                  2.       The limit upon the aggregate principal amount of the
                  Medium-Term Notes which may be authenticated and delivered
                  under the Indenture (except for Medium-Term Notes
                  authenticated and delivered upon registration of, transfer of,
                  or in exchange for, or in lieu of other Medium-Term Notes
                  pursuant to Sections 304, 305, 306, 906 or 1107 of the
                  Indenture) is $1,500,000,000. The Company may, without the
                  consent of the Holders of the Medium-Term Notes, issue
                  additional notes having the same ranking, interest rate,
                  Stated Maturity, CUSIP number and terms as to status,
                  redemption or otherwise as Medium-Term Notes that have been
                  previously issued, in which event such notes and such
                  previously issued Medium-Term Notes shall constitute one issue
                  for all purposes under the Indenture including without
                  limitation, amendments and waivers.

                  3.       The date on which the principal of each of the
                  Medium-Term Notes is payable shall be any Business Day (as
                  defined in the forms of Global Fixed Rate Note and Global
                  Floating Rate Note attached hereto as Exhibit A and
                  incorporated herein by reference) nine months or more from the
                  date of issuance as determined from time to time by any one of
                  Steven F. Udvar-Hazy, John L. Plueger, Alan H. Lund, Pamela S.
                  Hendry or Kurt Schwarz (each a "Designated Person").

<PAGE>

                  4.       The rate at which each of the Medium-Term Notes shall
                  bear interest shall be established by any one Designated
                  Person, and may be either a fixed interest rate (which may be
                  zero) (hereinafter, a "Fixed Rate Note") or may vary from time
                  to time in accordance with one of the interest rate formulas
                  more fully described in Exhibit A hereto (hereinafter, a
                  "Floating Rate Note") or otherwise as specified by a
                  Designated Person.

                  5.       Unless otherwise specified by a Designated Person,
                  the date from which interest shall accrue for each Medium-Term
                  Note shall be the respective date of issuance of each of the
                  Medium-Term Notes.

                  6.       The interest payment dates on which interest on the
                  Medium-Term Notes shall be payable are, in the case of Fixed
                  Rate Notes, April 15 and October 15, unless otherwise
                  specified by any Designated Person, and, in the case of
                  Floating Rate Notes, such dates as specified by any Designated
                  Person. The initial interest payment on each outstanding
                  Medium-Term Note shall be made on the first interest payment
                  date falling at least 15 days after the date the Medium-Term
                  Note is issued, unless otherwise specified by any Designated
                  Person.

                  7.       The regular record dates for the interest payable on
                  any Fixed Rate Note on any interest payment date shall be
                  April 1 and October 1, unless otherwise specified by any
                  Designated Person, and the regular record dates for the
                  interest payable on any Floating Rate Note on any interest
                  payment date shall be on the day 15 calendar days prior to any
                  such interest payment date, unless otherwise specified by any
                  Designated Person.

                  8.       Interest on the Fixed Rate Notes shall be computed on
                  the basis of a 360-day year of twelve (12) 30-day months.
                  Interest on the Floating Rate Notes shall be computed on the
                  basis set forth in Exhibit A hereto.

                  9.       The place or places where the principal (and premium,
                  if any) and interest on Medium-Term Notes shall be payable is
                  at the office of the Trustee, 101 Barclay Street, Ground Floor
                  Window, New York, New York 10286, provided that payment of
                  interest, other than at Stated Maturity (as defined in the
                  Indenture) or upon redemption or repurchase, may be made at
                  the option of the Company by check mailed to the address of
                  the person entitled thereto as such address shall appear in
                  the Security Register (as defined in the Indenture) and
                  provided further that (i) the Depositary (as designated
                  below), as holder of Global Securities (as defined in the
                  Indenture), shall be entitled to receive payments of interest
                  by wire transfer of immediately available funds, and (ii) a
                  Holder of $10,000,000 or more in aggregate principal amount of
                  certificated Medium-Term Notes, having identical Interest
                  Payment Dates, shall be entitled to receive payments of
                  interest, other than interest due at Stated Maturity or upon
                  redemption, by wire transfer in immediately available funds to
                  a designated account maintained in the United States upon
                  receipt by the Trustee of written instructions from such
                  Holder not later than the Regular Record Date for the

                                       2

<PAGE>

                  related Interest Payment Date. Such instructions shall remain
                  in effect with respect to payments of interest made to such
                  Holder on subsequent Interest Payment Dates unless revoked or
                  changed by written instructions received by the Trustee from
                  such Holder; provided that any such written revocation or
                  change which is received by the Trustee after a Regular Record
                  Date and before the related Interest Payment Date shall not be
                  effective with respect to the interest payable on such
                  Interest Payment Date.

                  10.      The date, if any, on which each Medium-Term Note may
                  be redeemed at the option of the Company shall be established
                  by any Designated Person.

                  11.      The terms under which any of the Medium-Term Notes
                  shall be repaid at the option of the Holder shall be as set
                  forth in the forms of the Global Fixed Rate Note and Global
                  Floating Rate Note attached hereto and the obligation of the
                  Company, if any, to repay any of the Medium-Term Notes at the
                  option of a Holder shall be established by any Designated
                  Person.

                  12.      The Medium-Term Notes shall be issued in fully
                  registered form in denominations of $1,000 or any amount in
                  excess thereof which is an integral multiple of $1,000.

                  13.      The principal amount of the Medium-Term Notes shall
                  be payable upon declaration of acceleration of the maturity
                  thereof pursuant to Section 502 of the Indenture.

                  14.      The Medium-Term Notes shall be issued as Global
                  Securities under the Indenture, unless otherwise specified by
                  any Designated Person, and The Depository Trust Company is
                  designated the Depositary under the Indenture for the
                  Medium-Term Notes.

                  15.      The terms of the Medium-Term Notes include the
                  provisions set forth in Exhibit A hereto.

                  16.      If specified by a Designated Person, Medium-Term
                  Notes may be issued as Amortizing Notes, Original Issue
                  Discount Notes or Indexed Notes, each as described in the
                  Prospectus Supplement dated April 23, 2004 to the Prospectus
                  dated March 19, 2004 relating to the Medium-Term Notes,
                  including any subsequent amendments or supplements thereto.

                  B.       The forms of the Global Fixed Rate Notes and the
Global Floating Rate Notes are attached hereto as Exhibit A.

                  C.       The Trustee is appointed as Paying Agent (as defined
in the Indenture) and The Bank of New York is appointed as Calculation Agent.

                  D.       The foregoing form and terms of the Medium-Term Notes
have been established in conformity with the provisions of the Indenture.

                                       3

<PAGE>

                  E.       Each of the undersigned has read the provisions of
Sections 301 and 303 of the Indenture and the definitions relating thereto and
the resolutions adopted by the Board of Directors of the Company and delivered
herewith. In the opinion of each of the undersigned, he or she has made such
examination or investigation as is necessary to enable him or her to express an
informed opinion as to whether or not all conditions precedent provided in the
Indenture relating to the establishment, authentication and delivery of a series
of Securities under the Indenture, designated as the Medium-Term Notes in this
Certificate, have been complied with. In the opinion of each of the undersigned,
all such conditions precedent have been complied with.

                  F.       The undersigned Assistant Secretary, by execution of
this Certificate, thereby certifies the actions taken by the Special Committee
of the Board of Directors of the Company in determining and setting the specific
terms of the Medium-Term Notes, and hereby further certifies that attached
hereto as Exhibits A, B, and C respectively, are the forms of certificates
representing the Global Fixed Rate Notes and Global Floating Rate Notes as duly
approved by the Special Committee of the Board of Directors of the Company, a
copy of resolutions duly adopted by the Board of Directors of the Company as of
June 11, 2003 and copies of resolutions duly adopted by the Special Committee of
the Board of Directors as of November 7, 2003 and April 23, 2004, pursuant to
which the terms of the Medium-Term Notes set forth above have been established.

                  G.       This certificate supersedes in its entirety the
Officers' Certificate, dated November 7, 2003, with respect to the Notes
previously delivered to you.

                  [Remainder of page intentionally left blank]

                                       4

<PAGE>

                  IN WITNESS WHEREOF, the undersigned have hereunto executed
this Certificate as of the date first above written.

                                    /s/ Alan H. Lund
                                    --------------------------------------------
                                    Alan H. Lund
                                    Vice Chairman and
                                    Chief Financial Officer

                                    /s/ Pamela S. Hendry
                                    --------------------------------------------
                                    Pamela S. Hendry
                                    Vice President, Treasurer and
                                    Assistant Secretary

                                       5Exhibit 10.12

                             AGREEMENT FOR SERVICES
                             ----------------------

THIS Agreement for Services is made as of this 18th day of March, 2004 (the
"Effective Date") by and between RegeneRx Biopharmaceuticals, Inc. with an
office located at 3 Bethesda Metro Center, Suit 700, Bethesda, Maryland 20814
("Sponsor") and PAREXEL International, LLC, with an office located at 195 West
Street, Waltham, MA 02451 ("PAREXEL").

                                   WITNESSETH

WHEREAS, Sponsor is engaged in research and development of pharmaceutical and
diagnostic products; and

WHEREAS, PAREXEL is engaged in the business of clinical trials management,
regulatory affairs consulting services, database management and statistical
analysis of clinical research and product development for pharmaceutical and
diagnostic products; and

WHEREAS, Sponsor desires to retain PAREXEL to assist in certain product
development activities.

NOW, THEREFORE, in consideration of the mutual promises and undertakings herein
set forth, the parties hereto agree as follows:

                               SECTION 1: SERVICES
                               -------------------

1.1: Sponsor hereby retains PAREXEL to provide the services outlined in Exhibit
A which, upon signature by both parties hereto, is/will be incorporated into and
made a part of this Agreement.

1.2: Subject to the terms and conditions hereinafter set forth, PAREXEL shall
diligently perform the services outlined in Exhibit A consistent with
professional industry standards.

1.3: PAREXEL shall also provide additional services specified in any future
Exhibit that may be agreed to between the parties in writing. If Sponsor wishes
to change the scope of the services covered by this Agreement or wishes to
obtain additional services not covered by this Agreement not listed in an
Exhibit, Sponsor shall so advise PAREXEL and shall submit specifications to
PAREXEL. After receipt of the specifications, PAREXEL may provide Sponsor with a
cost estimate for performing such services. All services provided by PAREXEL
shall be governed by the terms and conditions of this Agreement and by such
supplementary written amendments or Exhibits as may be, from time to time,
executed between the parties. In the event of a conflict between the provisions
of this Agreement and the Exhibit, the provisions of this Agreement shall
govern.

1.4: The parties acknowledge and agree that Affiliates of either party may
request or perform services, as the case may be, pursuant to this Agreement by
executing an Exhibit or other applicable contractual documents in accordance
with this Agreement. "Affiliate" means, with respect to a party to this
Agreement, any other legally recognizable entity directly or indirectly
controlling, controlled by, or

<PAGE>

under common control with such entity. Upon execution of an Exhibit, the parties
to the Exhibit shall assume the respective rights and obligations of this
Agreement for the purposes of such Exhibit."

                                 SECTION 2: TERM
                                 ---------------

This Agreement shall commence on the Effective Date and shall thereafter remain
in full force and effect until termination or expiration as provided herein.

                      SECTION 3: COMPENSATION AND EXPENSES
                      ------------------------------------

3.1: As compensation for its services hereunder, Sponsor shall pay PAREXEL the
amounts specified in Exhibit A attached hereto or any subsequent Exhibit agreed
to by the parties. Should the scope of a project described in any Exhibit
change, the PAREXEL service fees and any related pass-through expenses to be
paid by Sponsor pursuant to such Exhibit will be adjusted as mutually agreed
upon in writing by Sponsor and PAREXEL.

3.2: Sponsor will reimburse PAREXEL for all travel, third party payments (if
applicable), printing, shipping, teleconference and any other reasonable
out-of-pocket expenses (collectively, "pass-through expenses") incurred by
PAREXEL personnel at the request of Sponsor.

3.3: PAREXEL shall be responsible for taxes based on its net income. All other
taxes [taxes applicable to travel and expense charges] shall be the
responsibility of Sponsor and such taxes shall not be included in the PAREXEL
service fees payable hereunder.

3.4: Sponsor acknowledges that, as part of PAREXEL's performance, under this
Agreement, PAREXEL may enter into contracts with investigators on behalf of
Sponsor. PAREXEL will assume responsibility for administering and disbursing
payments to the investigators as outlined in Exhibit A or any future Exhibit
attached hereto. In no event shall an investigator be construed to be PAREXEL's
subcontractor or agent. Sponsor will provide adequate funds to PAREXEL in
advance for such investigator payments in accordance with a schedule to be
mutually agreed upon between the parties. In no event will PAREXEL be required
to disburse payments to any third parties if sufficient advance funds are not
available to cover such disbursements. Any remaining funds will be returned to
Sponsor after termination of each study as soon as all obligations to the
investigators have been satisfied. In the event the funds advanced by Sponsor
pursuant to this Section 3.4 are insufficient to cover such investigator
payments, Sponsor will promptly pay to PAREXEL the additional amounts required.
PAREXEL will provide Sponsor with reports on disbursements to investigators
within thirty (30) days after the end of each calendar quarter.

3.5: All payments for PAREXEL service fees and pass-through costs under this
Agreement shall be made within thirty (30) days after receipt of invoice except
that all third party payments shall be made consistent with Section 3.4.

<PAGE>

                           SECTION 4: CONFIDENTIALITY
                           --------------------------

Each party hereto understands that the other's relationship with its clients,
officers and employees is one of confidence and that during the period of this
agreement between PAREXEL and Sponsor, either party may receive, or may have
already received, knowledge of, or access to, information which relates to the
business, operations, products, or plans of the other or of its clients and
which is not known to the general public (hereinafter "Confidential
Information"). Except as necessary pursuant to the purpose of this Agreement,
the receiving party will not at any time, without the prior written consent of
the disclosing party, (a) use the Confidential Information for any purpose other
than the purpose related to this Agreement, or (b) disclosure any Confidential
Information to any other person or entity, or (c) use any Confidential
Information for the receiving party's own benefit or the benefit of any other
person or entity. The foregoing obligations shall not apply to information
which: (i) was known to the receiving party prior to receipt from the disclosing
party; (ii) is or lawfully becomes generally available to the public; (iii) is
lawfully acquired from third parties who have a right to disclosure such
information; (iv) by mutual written agreement is released from a confidential
status; (v) the receiving party is required by law to release, provided, the
disclosing party is given prior written notice of such request; or (vi) is
independently developed by the receiving party without use of the Confidential
Information.

                             SECTION 5: TERMINATION
                             ----------------------

5.1: This Agreement or any particular Exhibit(s) to this Agreement, may be
terminated by either party upon material default in performance of the other
party, provided that any defaulting party shall be given not less than ninety
(90) days prior written notice of default and the opportunity to cure the
default during such period.

5.2: This Agreement or any particular Exhibit(s) to this Agreement, may be
terminated by either party without cause upon one-hundred-twenty (120) days
prior written notice to the other party.

5.3: In the event that, pursuant to this Section 5, this Agreement or any
Exhibit(s) thereto, is terminated prior to the completion of the services
contemplated thereunder, PAREXEL will cease providing services under the
Agreement or applicable Exhibit other than services and obligations which are
reasonable and necessary to safely close out the study ("closeout work"), and
will terminate then current third party obligations to the extent practicable.
Sponsor agrees that, upon termination, it shall no longer be entitled to the
project rates that were conditioned upon completion of the terminated project,
and furthermore agrees that it shall pay PAREXEL for all services performed in
accordance with this Agreement (including but not limited to closeout work) at
PAREXEL's prevailing billing rate, as well as all non-cancelable pass-through
expenses incurred through the closeout date. Any final payment still owed to
PAREXEL, or any refund due Sponsor pursuant to this Section shall be made by
Sponsor or PAREXEL, as applicable within thirty (30) days of the final
reconciliation invoice(s) from PAREXEL.

5.4: If not sooner terminated, this Agreement will expire the later of (5) years
from the Effective Date or upon completion of the work contemplated by all
Exhibits hereto.

<PAGE>

                           SECTION 6: INDEMNIFICATION
                           --------------------------

Sponsor agrees to defend, indemnify, and hold harmless PAREXEL, its subsidiaries
and affiliates, and their respective employees, directors, independent
contractors and agents against and from any third party claims, proceedings,
(which shall include, without limitation, any command to produce documents or
testimony) or investigations, including, without limitation, claims, proceedings
or investigations by administrative and governmental agencies, arising out of or
in connection with this Agreement, including, without limitation, amounts paid
in settlement of claims, proceedings, or investigations, and agrees to bear all
costs and expenses, including, without limitation, reasonable attorneys' fees,
incurred in connection with the defense or settlement of any such claim,
proceeding or investigation as such costs and expenses are incurred in advance
of judgment. Sponsor shall have no obligation to indemnify PAREXEL and PAREXEL
shall defend, indemnify and hold harmless Sponsor to the extent that any third
party claims, proceedings or investigations are based on PAREXEL's gross
negligence or willful misconduct. The party seeking indemnification shall
promptly notify the indemnifying party of any such claim and shall cooperate
with the indemnifying party in the defense of such claim.

                              SECTION 7: PUBLICITY
                              --------------------

7.1: The parties agree that they shall obtain the other party's prior written
approval before using each other's name, symbols and/or marks in any form of
publicity. Such obligation shall not apply to disclosures which either party is
required by law to make or regulatory submissions.

                        SECTION 8: INDEPENDENT CONTRACTOR
                        ---------------------------------

The relationship of the parties to each other under this Agreement shall be that
of an independent contractor, and nothing contained herein shall be construed to
be inconsistent with that relationship or status. The employees, and consultants
of one party hereto shall not be considered employees or agents of the other
party. This Agreement shall not constitute, create, or in any way be interpreted
as, a joint venture, partnership, or business organization of any kind.

                                SECTION 9: DELAYS
                                -----------------

9.1: Sponsor acknowledges that PAREXEL will require documents, drug supplies,
data, records, and cooperation by Sponsor in order to properly perform the
services hereunder and that PAREXEL is not responsible for errors, delays or
other consequences arising from the failure of Sponsor to provide same.

9.2: Sponsor also acknowledges that PAREXEL will not be responsible for any
default under this Agreement by reason of strikes, riots, wars, acts of
terrorism, fire, acts of God, acts in compliance with any law, or any other
cause beyond its reasonable control.

9.3: If Sponsor delays or suspends a project for a period of longer than one (1)
month due to no fault of PAREXEL and the parties mutually agree that certain
PAREXEL staff shall continue to be assigned to the project during the period of
such delay or suspension, and a monthly maintenance fee will be

<PAGE>

charged, in an amount mutually agreed upon by the parties. Such delay shall last
no longer than six (6) months after which time PAREXEL shall have the right to
terminate or amend this Agreement.

                              SECTION 10: OWNERSHIP
                              ---------------------

Sponsor shall retain full ownership rights in all information, reports and other
proprietary or protectable matters developed as part of the services performed
under this Agreement and relating exclusively to Sponsor's products and their
applications. PAREXEL shall retain full ownership rights to all templates,
manuals, processes, methodologies, programs and other materials developed or
licensed by PAREXEL, including any improvements thereto, which are related to
PAREXEL's business or services. Following completion of the services outlined in
an Exhibit, PAREXEL, at Sponsor's expense, will return client data or other
materials furnished to PAREXEL. All study documentation not returned to Sponsor
will be kept by PAREXEL, at Sponsor's expense, for at least two years after the
New Drug Application is approved.

                      SECTION 11: COMMUNICATIONS & PAYMENTS
                      -------------------------------------

11.1: Legal notices provided for in this Agreement shall be sent by first class
mail, postage prepaid, addressed to the following persons s:

To PAREXEL:

         PAREXEL International, LLC
         195 West Street
         Waltham, MA 02451
         ATTN:  General Counsel

To Sponsor:

         David Crockford, and
         J.J. Finkelstein
         RegeneRx Biopharmaceuticals, Inc.
         3 Bethesda Metro Center
         Suite 700
         Bethesda, Maryland 20814

11.2: Payments provided by Sponsor under this Agreement shall be sent to one of
the following addresses:

<TABLE>
<CAPTION>

------------------------------------------------------------------------------------------------
US Check Remittance Address:                    Wire Remittance:
---------------------------                     ---------------
<S>                                             <C>
                                                (within US use ABA; for International use SWIFT):
------------------------------------------------------------------------------------------------
PAREXEL International, LLC                      Beneficiary Bank: LaSalle National Bank
5329 Paysphere Circle                                             135 South LaSalle Street
Chicago, IL 60674                                                 Chicago, IL 60674
------------------------------------------------------------------------------------------------
                                                ABA:  071-000-505
Federal Tax ID Number: 04-3517643               SWIFT: LASLUS44
                                                Beneficiary Name:  PAREXEL International, LLC
                                                Beneficiary Account:  5800-333-022
------------------------------------------------------------------------------------------------

</TABLE>

<PAGE>

11.3: Any invoices and/or project specific information provided for in this
Agreement shall be sent by first class mail, postage prepaid, addressed to the
individual(s) identified in each applicable Exhibit.

                             SECTION 12: ASSIGNMENT
                             ----------------------

Neither party shall have the right to assign this Agreement or any of the rights
or obligations hereunder without the prior written consent of the other party,
which will not be unreasonably withheld.

                          SECTION 13: NON-SOLICITATION
                          ----------------------------

PAREXEL's staff are not nor shall they be deemed to be at any time during the
term of this Agreement the employees of Sponsor. Sponsor agrees that neither it
nor its subsidiaries or other affiliated companies shall directly or indirectly
solicit for employment, employ or otherwise retain staff of PAREXEL during the
term of this Agreement nor within the period of twelve (12) months following
termination of this Agreement.

                             SECTION 14: DISCLAIMER
                             ----------------------

14.1: PAREXEL makes no representation or warranty that the product covered by
this Agreement can, either during the term of this Agreement or thereafter, be
successfully developed or, if so developed, will received the required approval
by the U.S. Food and Drug Administration or other regulatory body. Sponsor
acknowledges that its obligations to make payment to PAREXEL under Section 3 is
independent of and shall not be effected by the results of the study.

14.2: Sponsor acknowledges that the services to be provided by PAREXEL hereunder
are based upon information supplied by both PAREXEL and Sponsor, among other
elements, accordingly, PAREXEL does not warrant such services to any
specifications, functions or other standards, except as expressly set forth in
this Agreement or any Exhibit attached hereto.

14.3: Each party's aggregate liability to the other, regardless of any theory of
liability, for all claims, breach or default under this Agreement, shall be
limited to proven, direct damages incurred. In no event shall either party be
liable for special, indirect, incidental or consequential damages, including,
without limitation, lost profits.

                         SECTION 15: DISPUTE RESOLUTION
                         ------------------------------

If a dispute arises between the parties relating to this Agreement, the parties
shall meet in good faith to attempt to resolve the dispute. In the event the
dispute is not resolved through negotiation within ten

<PAGE>

(10) days after said meeting, the parties shall submit to confidential,
non-binding mediation before a mutually acceptable mediator. Each party shall
designate at least one corporate officer with full authority to resolve the
dispute who shall attend and participate in the mediation. If after mediation,
the dispute remains unresolved, each party shall be free to pursue any available
appropriate remedy at law. Each party shall bear its own legal fees and any
costs incurred under this Section 15.

                              SECTION 16: DEBARMENT
                              ---------------------

PAREXEL represents that consistent with Section 306(a) and Section 306(b) of the
Federal Food, Drug and Cosmetic Act (21 U.S.C. ss. 335(a) and 335(b)), none of
its employees has been debarred and PAREXEL will not knowingly hire any debarred
individual for performing services under this Agreement.

                            SECTION 17: MISCELLANEOUS
                            -------------------------

17.1: This Agreement constitutes the entire understanding between the parties on
the subject matter defined herein and supersedes all prior contracts,
agreements, and understandings relating to the same subject matter between the
parties. No change or modification to this Agreement shall be effective unless
it is in writing and signed by a duly authorized officer of PAREXEL and Sponsor.

17.2: This Agreement shall be governed by and construed in accordance with the
laws of the State of Delaware, U.S.A., without regard to its conflict of laws
provisions.

17.3: The terms of Section 3, 4, 6, 7, 10, 13 and 14, and the parties'
obligations thereunder, shall survive termination or expiration of this
Agreement and completion of PAREXEL's services hereunder.

         IN WITNESS THEREOF, the following have caused this Agreement to be
executed by their respective duly authorized representatives effective as of
this day and year above written.

<TABLE>
<CAPTION>

Accepted by:                                         Accepted by:

PAREXEL INTERNATIONAL, LLC                           REGENERX BIOPHARMACEUTICALS, INC.

<S>                                                  <C>
Signature:  /s/ Josef H. von Rickenbach              Signature:  /s/ J.J. Finkelstein
           -----------------------------                         ---------------------
           Josef H. von Rickenbach                               Name: J.J. Finkelstein
           Chief Executive Officer and Chairman                  Title: President and CEO
           PAREXEL International, LLC

Date:            3/29/04                                         Date:    3/23/04

</TABLE>

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00065-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00065-of-00352.parquet"}]]